Hizentra (Immune Globulin Subcutaneous, Human 20% Liquid) is a subcutaneous immunoglobulin (SCIG) therapy used to treat patients with primary immunodeficiency (PI) diseases. Primary immunodeficiency diseases are a group of disorders caused by an impaired or malfunctioning immune system, making affected individuals more susceptible to infections and other immune-related complications.
Hizentra is a concentrated solution of immunoglobulin G (IgG) antibodies derived from human plasma. These antibodies are essential for maintaining a healthy immune system and fighting infections. Hizentra is administered via subcutaneous infusion, which means it is injected under the skin, typically in the fatty tissue of the abdomen or thigh. This method allows for a slow, steady release of the antibodies into the bloodstream.
The treatment schedule for Hizentra can vary depending on the individual patient’s needs, but it is usually administered once a week or every two weeks. The dose and frequency of administration are determined by a healthcare provider based on the patient’s body weight and specific medical condition.
Hizentra is generally well-tolerated, but like any medication, it can cause side effects. Some common side effects include:
-
- Injection site reactions (redness, swelling, itching, or pain)
- Headache
- Fatigue
- Nausea
- Fever
If you have PI and are considering Hizentra, discuss the benefits and potential side effects with your healthcare provider to determine if it is the right treatment option for you.